<p>MBX Biosciences, Inc.（納斯達克代碼：MBX - 獲取免費報告）的股票在週二交易中下跌了 8.8%。該公司的股價最低曾達到 35.87 美元，最後交易價為 36.5370 美元。在午盤交易中，約有 708,034 股被交易，較平均每日交易量 614,707 股增加了 15%。該股票此前收盤價為 40.08 美元。</p>
<p>獲取 <strong>MBX Biosciences</strong> 的提醒：</p>
<h2>更多 MBX Biosciences 新聞</h2>
<p>以下是本週影響 MBX Biosciences 的主要新聞：</p>
<ul>
<li>積極情緒：Citizens JMP 將 MBX Biosciences 的目標價從 76 美元上調至 86 美元，並重申了 <strong>市場表現優於大盤</strong> 的評級，表明當前水平有顯著上行空間。Citizens JMP 上調 MBX Biosciences 目標價</li>
<li>積極情緒：Truist Financial 也將其目標價從 50 美元上調至 70 美元，並維持 <strong>買入</strong> 評級，進一步增強了分析師對該股票的樂觀情緒。Truist 上調 MBX Biosciences 目標價</li>
<li>積極情緒：MBX 發佈了肥胖組合的更新，顯示 MBX-4291 的早期第一階段數據，包括第一組在 8 周內平均減重 7% 的結果，並支持潛在的每月一次給藥，這可能增強投資者對公司管線的信心。MBX 肥胖組合更新和第一階段數據</li>
<li>中性情緒：Lifesci Capital 做出了混合的預測調整：它將一些 2026 年季度預估下調，同時上調了第二季度的預估，並保持 <strong>強買</strong> 評級。這些修訂表明預期仍在演變，但該公司整體上仍持建設性態度。</li>
</ul>
<h2>分析師評級上調與下調</h2>
<p>多位股票分析師對 MBX 股票發表了評論。Weiss Ratings 在 4 月 21 日的報告中重申了對 MBX Biosciences 股票的 &#34;賣出（d-）&#34; 評級。花旗集團在週二的研究報告中重申了對 MBX Biosciences 股票的 &#34;跑贏大盤&#34; 評級。Lifesci Capital 在 3 月 31 日的研究報告中將 MBX Biosciences 股票的評級上調至 &#34;強買&#34;。TD Cowen 在 3 月 12 日的研究報告中重申了對 MBX Biosciences 股票的 &#34;買入&#34; 評級。最後，巴克萊在週二的研究報告中將 MBX Biosciences 股票的目標價從 66.00 美元上調至 70.00 美元，並給予該公司 &#34;增持&#34; 評級。一位投資分析師對該股票給予了強買評級，十位給予了買入評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 60.22 美元。</p>
<p><strong>查看我們最新的 MBX 股票報告</strong></p>
<h2>MBX Biosciences 股票表現</h2>
<p>該公司的市值為 17.6 億美元，市盈率為-16.74，貝塔值為 0.78。該公司的 50 日移動平均價格為 31.18 美元，200 日移動平均價格為 31.40 美元。</p>
<p>MBX Biosciences（納斯達克代碼：MBX - 獲取免費報告）最近在 3 月 12 日發佈了其財報。該公司報告每股收益（EPS）為-0.49 美元，超出分析師的共識預期-0.64 美元，超出幅度為 0.15 美元。分析師平均預測 MBX Biosciences, Inc. 本財年每股收益為-2.9 美元。</p>
<h2>MBX Biosciences 的內部買賣</h2>
<p>在其他 MBX Biosciences 的新聞中，首席執行官 P. Kent Hawryluk 於 3 月 13 日收購了 18,500 股該股票。該股票的收購均價為每股 28.41 美元，總價值為 525,585.00 美元。交易後，首席執行官直接持有該公司 486,777 股股票，價值約為 13,829,334.57 美元。這代表了其持股比例的 3.95% 的增長。該收購在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。</p>
<h2>機構投資者對 MBX Biosciences 的看法</h2>
<p>多家機構投資者最近調整了對 MBX 的持股。Geode Capital Management LLC 在第二季度將其在 MBX Biosciences 的持股增加了 27.0%。Geode Capital Management LLC 目前擁有 348,447 股該公司股票，價值 397.6 萬美元，此前在上個季度又購買了 73,989 股。Rhumbline Advisers 在第二季度將其在 MBX Biosciences 的持股增加了 171.6%。Rhumbline Advisers 目前擁有 23,662 股該公司股票，價值 27 萬美元，此前在上個季度又購買了 14,950 股。XTX Topco Ltd 在第二季度購買了價值約 135,000 美元的 MBX Biosciences 新股份。製造商人壽保險公司在第二季度將其在 MBX Biosciences 的持股增加了 73.8%。製造商人壽保險公司目前擁有 87,097 股該公司股票，價值 994,000 美元，此前在上個季度又購買了 36,987 股。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度將其在 MBX Biosciences 的持股增加了 40.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 9,329 股該公司股票，價值 106,000 美元，此前在上個季度又購買了 2,682 股。</p>
<h2>MBX Biosciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>我們是一家臨牀階段的生物製藥公司，專注於發現和開發用於治療內分泌和代謝疾病的新型精準肽療法。我們的公司由全球領先的專家創立，採用變革性的方法進行肽藥物的設計和開發。利用這一專業知識，我們設計了專有的精準內分泌肽™（PEPTM）平台，以克服未修飾和修飾肽療法的關鍵限制，並改善臨牀結果，簡化患者的疾病管理。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 MBX Biosciences</li>
<li>海軍催化劑點燃 Odysight 的增長引擎</li>
<li>AST SpaceMobile 因銀河第一季度業績不佳而暴跌：垂直整合能拯救這家 SpaceX 競爭對手嗎？</li>
<li>Axon 在財報發佈後大幅上漲，但仍比高點下跌超過 50%</li>
<li>可能重新定義蘋果夏季反彈的事件</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元於 MBX Biosciences 嗎？</h2>
<p>在考慮 MBX Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MBX Biosciences 並不在名單上。</p>
<p>雖然 MBX Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>MBX Biosciences（納斯達克代碼：MBX）股價下跌 8.8%，至 36.54 美元，交易量增加。分析師們依然持樂觀態度，Citizens JMP 將其目標價上調至 86 美元，Truist Financial 則上調至 70 美元，均維持積極評級。該公司報告了其肥胖藥物 MBX-4291 的有希望的第一階段數據。儘管 Lifesci Capital 的預測存在分歧，但整體情緒依然看漲，市場共識評級為 “適度買入”，平均目標價為 60.22 美元。首席執行官 P. Kent Hawryluk 最近增加了在公司的持股，購買了 18,500 股</p>

<p>Shares of MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) were down 8.8% during trading on Tuesday . The company traded as low as $35.87 and last traded at $36.5370. Approximately 708,034 shares were traded during mid-day trading, an increase of 15% from the average daily volume of 614,707 shares. The stock had previously closed at $40.08.</p>
<div class="lb-trans"><p>MBX Biosciences, Inc.（納斯達克代碼：MBX - 獲取免費報告）的股票在週二交易中下跌了 8.8%。該公司的股價最低曾達到 35.87 美元，最後交易價為 36.5370 美元。在午盤交易中，約有 708,034 股被交易，較平均每日交易量 614,707 股增加了 15%。該股票此前收盤價為 40.08 美元。</p>
</div><p>Get <strong>MBX Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>MBX Biosciences</strong> 的提醒：</p>
</div><h2>More MBX Biosciences News</h2>
<div class="lb-trans"><h2>更多 MBX Biosciences 新聞</h2>
</div><p>Here are the key news stories impacting MBX Biosciences this week:</p>
<div class="lb-trans"><p>以下是本週影響 MBX Biosciences 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Citizens JMP raised its price target on MBX Biosciences to $86 from $76 and reiterated a <strong>market outperform</strong> rating, signaling substantial upside from current levels. Citizens JMP price target raised on MBX Biosciences</li>
<li>Positive Sentiment: Truist Financial also boosted its price target to $70 from $50 and maintained a <strong>buy</strong> rating, adding to the bullish analyst sentiment around the stock. Truist raises MBX Biosciences price target</li>
<li>Positive Sentiment: MBX released an obesity portfolio update showing early Phase 1 data for MBX-4291, including mean weight loss of 7% at 8 weeks in the first cohort and support for potential once-monthly dosing, which could strengthen investor confidence in the company’s pipeline. MBX obesity portfolio update and Phase 1 data</li>
<li>Neutral Sentiment: Lifesci Capital made mixed forecast changes: it nudged some 2026 quarterly estimates lower while raising its Q2 estimate and keeping a <strong>Strong-Buy</strong> rating. The revisions suggest expectations are still evolving, but the firm remains constructive overall.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Citizens JMP 將 MBX Biosciences 的目標價從 76 美元上調至 86 美元，並重申了 <strong>市場表現優於大盤</strong> 的評級，表明當前水平有顯著上行空間。Citizens JMP 上調 MBX Biosciences 目標價</li>
<li>積極情緒：Truist Financial 也將其目標價從 50 美元上調至 70 美元，並維持 <strong>買入</strong> 評級，進一步增強了分析師對該股票的樂觀情緒。Truist 上調 MBX Biosciences 目標價</li>
<li>積極情緒：MBX 發佈了肥胖組合的更新，顯示 MBX-4291 的早期第一階段數據，包括第一組在 8 周內平均減重 7% 的結果，並支持潛在的每月一次給藥，這可能增強投資者對公司管線的信心。MBX 肥胖組合更新和第一階段數據</li>
<li>中性情緒：Lifesci Capital 做出了混合的預測調整：它將一些 2026 年季度預估下調，同時上調了第二季度的預估，並保持 <strong>強買</strong> 評級。這些修訂表明預期仍在演變，但該公司整體上仍持建設性態度。</li>
</ul>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>A number of equities analysts have commented on MBX shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of MBX Biosciences in a report on Tuesday, April 21st. Citigroup restated an &#34;outperform&#34; rating on shares of MBX Biosciences in a research note on Tuesday. Lifesci Capital upgraded shares of MBX Biosciences to a &#34;strong-buy&#34; rating in a research note on Tuesday, March 31st. TD Cowen restated a &#34;buy&#34; rating on shares of MBX Biosciences in a research note on Thursday, March 12th. Finally, Barclays upped their target price on shares of MBX Biosciences from $66.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $60.22.</p>
<div class="lb-trans"><p>多位股票分析師對 MBX 股票發表了評論。Weiss Ratings 在 4 月 21 日的報告中重申了對 MBX Biosciences 股票的 &#34;賣出（d-）&#34; 評級。花旗集團在週二的研究報告中重申了對 MBX Biosciences 股票的 &#34;跑贏大盤&#34; 評級。Lifesci Capital 在 3 月 31 日的研究報告中將 MBX Biosciences 股票的評級上調至 &#34;強買&#34;。TD Cowen 在 3 月 12 日的研究報告中重申了對 MBX Biosciences 股票的 &#34;買入&#34; 評級。最後，巴克萊在週二的研究報告中將 MBX Biosciences 股票的目標價從 66.00 美元上調至 70.00 美元，並給予該公司 &#34;增持&#34; 評級。一位投資分析師對該股票給予了強買評級，十位給予了買入評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 &#34;適度買入&#34;，平均目標價為 60.22 美元。</p>
</div><p><strong>View Our Latest Stock Report on MBX</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 MBX 股票報告</strong></p>
</div><h2>MBX Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>MBX Biosciences 股票表現</h2>
</div><p>The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -16.74 and a beta of 0.78. The business's 50 day moving average price is $31.18 and its 200-day moving average price is $31.40.</p>
<div class="lb-trans"><p>該公司的市值為 17.6 億美元，市盈率為-16.74，貝塔值為 0.78。該公司的 50 日移動平均價格為 31.18 美元，200 日移動平均價格為 31.40 美元。</p>
</div><p>MBX Biosciences (NASDAQ:MBX - Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.15. On average, analysts forecast that MBX Biosciences, Inc. will post -2.9 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MBX Biosciences（納斯達克代碼：MBX - 獲取免費報告）最近在 3 月 12 日發佈了其財報。該公司報告每股收益（EPS）為-0.49 美元，超出分析師的共識預期-0.64 美元，超出幅度為 0.15 美元。分析師平均預測 MBX Biosciences, Inc. 本財年每股收益為-2.9 美元。</p>
</div><h2>Insider Buying and Selling at MBX Biosciences</h2>
<div class="lb-trans"><h2>MBX Biosciences 的內部買賣</h2>
</div><p>In other MBX Biosciences news, CEO P. Kent Hawryluk acquired 18,500 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average price of $28.41 per share, with a total value of $525,585.00. Following the transaction, the chief executive officer directly owned 486,777 shares in the company, valued at approximately $13,829,334.57. This represents a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link.</p>
<div class="lb-trans"><p>在其他 MBX Biosciences 的新聞中，首席執行官 P. Kent Hawryluk 於 3 月 13 日收購了 18,500 股該股票。該股票的收購均價為每股 28.41 美元，總價值為 525,585.00 美元。交易後，首席執行官直接持有該公司 486,777 股股票，價值約為 13,829,334.57 美元。這代表了其持股比例的 3.95% 的增長。該收購在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。</p>
</div><h2>Institutional Investors Weigh In On MBX Biosciences</h2>
<div class="lb-trans"><h2>機構投資者對 MBX Biosciences 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of MBX. Geode Capital Management LLC grew its position in shares of MBX Biosciences by 27.0% during the 2nd quarter. Geode Capital Management LLC now owns 348,447 shares of the company's stock valued at $3,976,000 after buying an additional 73,989 shares during the last quarter. Rhumbline Advisers grew its position in shares of MBX Biosciences by 171.6% during the 2nd quarter. Rhumbline Advisers now owns 23,662 shares of the company's stock valued at $270,000 after buying an additional 14,950 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of MBX Biosciences during the 2nd quarter valued at about $135,000. The Manufacturers Life Insurance Company grew its position in shares of MBX Biosciences by 73.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 87,097 shares of the company's stock valued at $994,000 after buying an additional 36,987 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of MBX Biosciences by 40.3% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company's stock valued at $106,000 after buying an additional 2,682 shares during the last quarter.</p>
<div class="lb-trans"><p>多家機構投資者最近調整了對 MBX 的持股。Geode Capital Management LLC 在第二季度將其在 MBX Biosciences 的持股增加了 27.0%。Geode Capital Management LLC 目前擁有 348,447 股該公司股票，價值 397.6 萬美元，此前在上個季度又購買了 73,989 股。Rhumbline Advisers 在第二季度將其在 MBX Biosciences 的持股增加了 171.6%。Rhumbline Advisers 目前擁有 23,662 股該公司股票，價值 27 萬美元，此前在上個季度又購買了 14,950 股。XTX Topco Ltd 在第二季度購買了價值約 135,000 美元的 MBX Biosciences 新股份。製造商人壽保險公司在第二季度將其在 MBX Biosciences 的持股增加了 73.8%。製造商人壽保險公司目前擁有 87,097 股該公司股票，價值 994,000 美元，此前在上個季度又購買了 36,987 股。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度將其在 MBX Biosciences 的持股增加了 40.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前擁有 9,329 股該公司股票，價值 106,000 美元，此前在上個季度又購買了 2,682 股。</p>
</div><h2>MBX Biosciences Company Profile</h2>
<div class="lb-trans"><h2>MBX Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.</p>
<div class="lb-trans"><p>我們是一家臨牀階段的生物製藥公司，專注於發現和開發用於治療內分泌和代謝疾病的新型精準肽療法。我們的公司由全球領先的專家創立，採用變革性的方法進行肽藥物的設計和開發。利用這一專業知識，我們設計了專有的精準內分泌肽™（PEPTM）平台，以克服未修飾和修飾肽療法的關鍵限制，並改善臨牀結果，簡化患者的疾病管理。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than MBX Biosciences</li>
<li>Navy Catalyst Ignites Odysight’s Growth Engine</li>
<li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li>
<li>Axon Surged After Earnings and Is Still Down Over 50% From Highs</li>
<li>The Event That Could Redefine Apple’s Summer Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 MBX Biosciences</li>
<li>海軍催化劑點燃 Odysight 的增長引擎</li>
<li>AST SpaceMobile 因銀河第一季度業績不佳而暴跌：垂直整合能拯救這家 SpaceX 競爭對手嗎？</li>
<li>Axon 在財報發佈後大幅上漲，但仍比高點下跌超過 50%</li>
<li>可能重新定義蘋果夏季反彈的事件</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MBX Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於 MBX Biosciences 嗎？</h2>
</div><p>Before you consider MBX Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MBX Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MBX Biosciences 並不在名單上。</p>
</div><p>While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MBX Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MBX Biosciences（NASDAQ:MBX）股價下跌 8.8% - 事情經過如下